Pathology, Molecular Diagnostics, Research: Expertise

Urologic Pathology Publications

  1. Mitchell, J.R., Smith, C.V., Hughes, H., Lenz, M., Jaeschke, H., Shappell, S., Michael, L., Entman, M.L.: No evidence for reactive oxygen damage in ischemia-reflow injury. Trans. Assoc. Am. Physicians 99: 54-61, 1987.
  2. Lenz, M.L., Michael, L.H., Smith, C.V., Hughes, H., Shappell, S.B., Taylor, A.A., Entman, M.L., Mitchell, J.R.: Glutathione disulfide formation and lipid peroxidation during cardiac ischemia and reflow in the dog in vivo. Biochem. Biophys. Res. Comm. 164: 722-727, 1989.
  3. Shappell,S.B., Taylor, A.A., Hughes, H., Mitchell, J.R., Anderson, D.C., Smith, C.W.: Comparison of antioxidant and non-antioxidant lipoxygenase inhibitors on neutrophil function. Implications for pathogenesis of myocardial reperfusion injury. J. Pharm. Exp. Ther. 252: 531-538, 1990.
  4. Shappell, S.B., Toman, C., Anderson, D.C., Taylor, A.A., Entman, M.L., Smith, C.W.: Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J. Immunol. 144: 2702-2711, 1990.
  5. Entman, M.L., Youker, K., Shappell, S.B., Siegel, C., Rothlein, R., Dreyer, W.J., Schmalstieg, F.C., Smith, C.W.: Neutrophil adherence to isolated adult canine myocytes: Evidence for a CD-18 dependent mechanism. J. Clin. Invest. 85: 1497-1506, 1990.
  6. Taylor, A.A., Shappell, S.B.: Rective oxygen species, neutrophil and endothelial adherence molecules, and lipid-derived inflammatory mediators in myocardial ischemia-reflow injury. In Smith, C.V., Moslen, M.T. (eds.): Free Radical Mechanisms of Tissue Injury, American Chemical Society Symposium Series, CRC Press, Florida; Chapter 5, pp. 65-141, 1992.
  7. Entman, M.L., Youker, K., Shoji, T., Kukielka, G., Taylor, A.A., Shappell, S.B., Smith, C.W.: Neutrophil induced oxidative injury of cardiac myocytes: A compartmented system requiring CD11b/CD18-ICAM-1 adherence. J. Clin. Invest. 90: 1335-1345, 1992.
  8. Shappell, S.B., Smith, C.W.: Acute inflammatory response: granulocyte migration and activation. In Wegner, C.D. (ed): Adhesion Molecules, Academic Press Limited; Chapter 3, pp. 29-70, 1994.
  9. Sarman, G., Shappell, S.B., Mason, E.O., Jr., Smith, C.W., Kaplan, S.L.: Susceptibility to local and systemic bacterial infections in ICAM-1 deficient transgenic mice. J. Infect. Dis. 172:1001-1006, 1995.
  10. Truong, L.D., Petrusevka, G., Yang, G., Gurpinar, T., Shappell, S., Lechago, J., Rouse, D., Suki, W.N.: The kinetics of cell apoptosis and proliferation in experimental chronic obstructive uropathy. Kidney Int. 50 : 200-207,1996.
  11. Truong, L.D., Shappell, S.B., Solez, K.: Adhesion molecules as markers of acute cellular rejection of renal allografts. Transplant Proceedings 28: 519-522, 1996.
  12. Truong, L.D., Shappell, S., Barrios, R., Gonzalez, J., Suki, W.N., Solez, K.: Immunohistochemistry and molecular biology markers of renal transplant rejection. Diagnostic Applications. Transplantation Reviews 10: 187-208,1996.
  13. Hornquist, C.E., Lu, X., Rogers-Fani, P.M., Rudolph, U., Shappell, S., Birnbaumer, L., Harriman, G.R.: Gαi2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J. Immunol. 158: 1068-1077, 1997.
  14. Shappell, S.B., Myrthil, G., Fogo, A.: An adolescent with relapsing nephrotic syndrome: Minimal-change disease versus focal-segmental glomerulosclerosis versus C1q nephropathy. Am. J. Kid. Dis. 29:966-970, 1997.
  15. Lu, H., Smith, C.W., Perrard, J., Bullard, D., Tang, L., Shappell, S.B., Entman, M.L., Beaudet, A.L., Ballantyne, C.M.: LFA-1 is sufficient in mediating neutrophil emigration in Mac-1 deficient mice. J. Clin. Invest. 99:: 1340-1350, 1997.
  16. Goral, S., Felgar, R., Shappell, S.: Posttransplant lymphoproliferative disorder in a renal allograft recipient. Am. J. Kid. Dis. 30: 301-307, 1997.
  17. Shappell, S.B., Gurpinar, T., Lechago, J., Suki, W.N., Truong, L.D.: Chronic obstructive uropathy in severe combined immunodeficient (SCID) mice. Lymphocyte infiltration is not required for progressive tubulointerstitial injury. J. Am. Soc. Nephrol., 9: 1008-1017, 1998.
  18. Fogo, A., Shappell, S.: Nephrotic syndrome in a young post partum woman. Am. J. Kid. Dis., 31: 723-728, 1998.
  19. Paueksakon, P., Grewal, M., Shappell, S.: Nephrotic range proteinuria and hematuria in a white bisexual male. Am J Kid Dis, 33:607-612, 1999.
  20. Grossklaus, D.J., Dutta, S.C., Shappell, S.B., Kirchner, F.K.: Cutaneous mucormycosis presenting as a penile lesion in a patient with acute myeloblastic leukemia. J. Urol., 161:1906-1907, 1999.
  21. Shappell, S.B., Mendoza, L.H., Gurpinar, T., Smith, C.W., Suki, W.N., Truong, L.D.: Expression of adhesion molecules in kidney with experimental chronic obstructive uropathy: The pathogenic role of ICAM-1 and VCAM-1. Nephron, 85:156-166, 2000.
  22. Shappell, S.B., Boeglin, W.E., Olson, S.J., Kasper, S., Brash, A.R.: 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am. J. Pathol., 155:235-245, 1999.
  23. Brash A. R., Jisaka, J., Boeglin, W. E., Chang, M. S., Keeney, D. S., Nanney, L. B., Kasper, S., Matusik, R.J., Olson, S.J., Shappell, S. B: Investigation of a second 15S-lipoxygenase in humans and its expression in epithelial tissues. Adv Exp Med Biol 469:83-89, 1999.
  24. Nogueira, M., Cartwright, J., Jr., Horn, K., Doe, N., Shappell, S., Barrios, R., Coroneos, E., Truong, L.D.: Thin basement membrane disease with heavy proteinuria or nephrotic syndrome at presentation. Am J Kidney Dis 35:E15, 2000.
  25. Wang, J-L., Cheng, H-F., Shappell, S., Harris, R.C.: A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int., 57:2334-2342, 2000.
  26. Komhoff, M., Guan, Y., Shappell, H.W., Davies, L., Jack, G., Shyr, Y., Koch, M., Shappell, S.B., Breyer, M.D.: Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol, 157:29-35, 2000.
  27. Matusik, R.J., Masumori, N., Thomas, T., Case, T., Paul, M., Kasper, S., Shappell, S.B.: Transgenic mouse models of prostate cancer. In Contemporary Endocrinology: Transgenics in Endocrinology, edited by Matzuk, M., Brown, C.W., and Kumar, T.R., Humana Press, Inc., Totowa, N.J., 2001, pages 401-425.
  28. Jack, G.S., Brash, A.R., Olson, S.J., Manning, S., Coffey, C.S, Smith, J.A., Jr., Shappell, S.B.: Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: Correlation with grade and expression in high grade prostatic intraepithelial neoplasia. Hum Pathol, 31:1146-1154, 2000.
  29. Shappell, S.B., Masumori, N., Thomas, T., Case, T., Paul, M., Kasper, S., Matusik, R.J.: Transgenic mouse models of prostate carcinoma: Anatomic, histopathologic, and molecular considerations. In Prostate Cancer: Scientific and Clinical Aspects. Bridging the Gap, edited by Abel, P.D., Lalani, E-N., Imperial College Press, in press.
  30. Grossklaus, D.J., Shappell, S.B., Gautam, S., Smith, J.A., Jr., Cookson, M.S.: Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. J Urol, 165: 455-458, 2001.
  31. Shappell, S.B., Gupta, R.A., Manning, S., Whitehead, R., Boeglin, W.E., Schneider, C., Case, T., Price, J., Jack, G. S., Wheeler, T.M., Matusik, R.J., Brash, A.R., DuBois, R.N.: 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res, 61:497-503, 2001.
  32. Masumori, N., Thomas, T.Z., Chaurand, P., Case, T., Paul, M., Kasper, S., Caprioli, R.M., Tsukamoto, T., Shappell, S.B., Matusik, R.J.: A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res, 61: 2239-2249, 2001.
  33. Grossklaus, D.J., Shappell, S.B., Adams, MC, Brock, JW, III, Pope, JC, IV. Small intestinal submucosa as a urethral coverage layer. J Urol, 166: 636-639, 2001.
  34. Dutta, S.C., Smith, J.A., Jr., Shappell, S.B., Coffey, C.S., Chang, S.S., Cookson, M.S. Clinical understaging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol, 166: 490-493, 2001.
  35. Shappell, S.B., Manning, S., Boeglin, W.E., Guan, Y.-F., Roberts, R.L., Davis, L., Olson, S.J., Jack, G.S., Coffey, C.S., Wheeler, T.M., Breyer, M.D., Brash, A.R.: Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia, 3: 287-303, 2001.
  36. Shappell, S.B., Keeney, D.S., Zhang, J., Page, R., Olson, S.J., Brash, A.R.: 15-lipoxygenase-2 (15-LOX-2) expression in benign and neoplastic sebaceous glands and other cutaneous adnexa. J Invest Dermatol, 117: 36-43, 2001.
  37. Grossklaus, D.J., Coffey, C.S., Shappell, S.B., Jack, G.S., , Cookson, M.S.: Prediction of tumor volume and pathologic stage in radical prostatectomy specimens is not enhanced by increasing the number of prostate needle biopsy cores. Br J Urol International, 88(7): 722-726, 2001.
  38. Balyakina, E.V., Chen, D., Lawrence, M.L., Manning, S., Parker, R.E., Shappell, S.B., Meyrick, B. ET-1 receptor gene expresion and distribution in L1 and L2 cells from hypertensive sheep pulmonary artery. Am J Physiol: Lung Cell Mol Physiol, 283:L42-L51, 2002.
  39. Grossklaus,D.J., Coffey, C.S., Shappell, S.B , Jack, G.S., Chang, S.S., and Cookson, M.S.: Percent of cancer in the biopsy set correlates with pathologic findings after prostatectomy. J. Urol., 167: 2032-2036, 2002.
  40. Jack, G.S., Cookson, M.S. , Coffey, C.S., Vader, V., Roberts, R.L., Chang, S.S., Smith, J.A., Jr., Shappell, S.B.: Pathologic parameters in radical prostatectomies of clinical stage T1c vs. T2 prostate adenocarcinoma. Reduced pathologic stage and Increased detection of transition zone tumors. J. Urol., 168: 519-524, 2002.
  41. Parekh, D.J., Jung, C., Roberts, R., Shappell, S., Smith JA Jr. Primary neuroendocrine carcinoma of the urethra. Urology, 60: 1111, 2002.
  42. Grossklaus, D.J., Smith, J.A., Shappell, S.B., Coffey, C.S., Chang, S.S., Cookson, M.S. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. Urol Oncol, 7(5):195-198, 2002.
  43. Goral, S., Ynares, C., Shappell, S.B., Snyder, S., Feurer, I.D., Kazancioglu, R., Fogo, A.B., Helderman, J.H. Recurrent lupus nephritis in renal transplant recipients revisited: It is not rare. Transplantation, 75(5):651-656, 2003.
  44. Gupta, R.A., Sarraf, P., Brockman, J.A., Shappell, S.B., Raftery, L.A., Willson, T.M., DuBois, R.N.: Peroxisome proliferator-activated receptor γ and transforming growth factor-β pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J. Biol. Chem., 278:7431-7438, 2003.
  45. Xu, X.-C, Shappell, S.B., Liang, Z., Song, S., Menter, D., Subbarayan, V., Iyengar, S., Tang, D.G., Lippman, S.M.: Reduced 15S-Lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia, 5(2):121-127, 2003.
  46. Tu, W.H., Thomas, T.Z., Masumori, N., Gorska, A., Bhowmick, N.A., Shyr, Y., Kasper, S., Case, T., Roberts, R.L., Shappell, S.B., Moses, H.L, Matusik, R.J. The loss of TGF-β signaling promotes prostate cancer metastasis. Neoplasia, 5(3):267-277,2003.
  47. Shappell, S.B., Olson, S.J., Hannah, S.E., Manning, S., Roberts, R.L, Masumori, N, Jisaka, M., Boeglin, W.E., Vader, V., Dave, D. S., Shook, M.F.,Thomas, T.Z., Funk, C., Brash, A.R., Matusik, R.J.: Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res, 63(9):2256-2267, 2003.
  48. Kasper, S., Tu, W., Roberts, R.L., Shappell, S.B.: Transgenic mouse models for prostate cancer. Identification of an androgen-dependent promoter and creation and characterization of the long probasin promoter-Large T antigen (LPB-Tag) model. Methods Mol Med, 81:113-47, 2003.
  49. Xu, Y., Iyengar, S, Roberts, R.L., Shappell, S.B., Peehl, D.M.: Primary culture model of peroxisome proliferator-activated receptor γ (PPARγ) activity in prostate cancer cells. J. Cell Physiol., 196:131-143, 2003.
  50. Paueksakon, P., Revelo, M.P., Horn, R.G., Shappell, S., Fogo, A.B.: Monoclonal gammopathy: Significance and possible causality in renal disease. Am J Kid Dis, 42:87-95, 2003.
  51. Bhatia, B., Maldonado, C.J., Tang, S., Chandra, D., Klein, R.D., Chopra, D., Shappell, S.B., Yang, P., Newman, R.A., Tang, D.G. Subcellular loclization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J. Biol. Chem., J Biol Chem, 278: 25091-25100, 2003.
  52. Cole, E.E., DeSouza, R., Shappell, S., Cookson MS. Primary renal carcinoid tumor. J Urol., 171(1): 338, 2004.
  53. Masumori, N., Tsuchiya, K., Tu, W.H., Lee, C., Kasper, S., Tsukamoto, T., Shappell, S.B., Matusik, R.J.: An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J. Urol., 171(1): 439-42, 2004.
  54. Revelo, M.P., Cookson, M.S., Chang, S.S., Shook, M.F., Smith, J.A., Jr., Shappell, S.B. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: Implications for possible apical sparing surgery. J. Urol., 171(2): 646-651, 2004.
  55. Shappell, S.B., Thomas, G.V., Roberts, R.L., Herbert, R., Rubin, M.A., Humphrey, P.A., Ittmann, M.M., Sundberg, J.P., Rozengurt, N., Barrios, R.J., Ward, J.M., Cardiff, R.D.: Prostate pathology of genetically engineered mice: Definitions and Classification. The Consensus Report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res, 64: 2270-2305, 2004.
  56. Gonzalez, A. L., Roberts, R. L., Massion, P.P., Olson, S.J., Shyr, Y., Shappell, S.B. 15-lipoxygenase-2 expression in benign and neoplastic lung: An immunohistochemical study and correlation with tumor grade and proliferation.. Hum Pathol., 35(7):840-849, 2004.
  57. Shuford, M.D., Chang, S.S., Cookson, M.S., Shintani, A.K., Tsiatis, A., Smith, J.A., Jr., Shappell, S.B. Adverse prognostic significance of capsular incision with radical retropubic prostatectomy. J Urol, 172: 119-123, 2004.
  58. Jiang, M., Shappell, S.B., Hayward, S.W. Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer. J Cell Biochem. 15;91(3):513-527, 2004.
  59. Bhowmick, N.A., Chytil, A., Plieth, D., Gorska, A.E., Dumont, N., Shappell, S., Washington, M.K., Neilson, E.G., Moses, H.L. TGF-{beta} Signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 303(5659):848-851, 2004.
  60. Jin, R.J., Wang, Y., Masumori, N., Ishii, K., Tsukamoto, T., Shappell, S.B., Hayward, S.W., Kasper, S., Matusik, R.J. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 64 (15):5489-5495, 2004.
  61. Kelavkar, U.P., Glasgow, W., Olson, S.J., Foster, B.A.., Shappell, S.B. Overexpression of 12/15-lipoxygenase (12/15-LO); an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mouse. Neoplasia, 6(6):821-830, 2004.
  62. Chang, M.S., Schneider, C., Roberts, R.L., Shappell, S.B., Haselton, F.R., Boeglin, W.E., Brash, A.R. Detection and subcellular localization of two 15S-lipoxygenases in human cornea. Invest Ophthalmol Vis Sci, 46(3):849-856, 2005.
  63. Wang, Y. Revelo, M.P., Sudilovsky, D., Cao, M., Chen, W.G., Goetz, L., Xue, H., Sadar, M., Shappell, S.B., Cunha, G.R., Hayward, S.W. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate, 64(2):149-159, 2005.
  64. Gao, N., Ishii, K., Mirosevich, J., Kuwajima, S., Oppenheimer, S.R., Roberts, R.L., Jiang, M., Yu, X., Shappell, S.B., Caprioli, R.M., Stoffel, M., Hayward, S.W., Matusik, R.J. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development, 132(15):3431-3443, 2005.
  65. Ishii, K., Shappell, S.B., Matusik, R.J., Hayward, S.W. Use of tissue recombination to predict phenotypes of transgenic mouse models of prostate carcinoma. Lab Invest, 85(9):1086-1103, 2005.
  66. Mirosevich, J., Gao, N., Gupta, A., Shappell, S.B., Jove, R., Matusik, R.J. Expression and role of Foxa proteins in prostate cancer. Prostate, 66(10):1013-1028, 2006.
  67. Lu, Q., Dobbs, L.J., Gregory, C.W., Lanford, G.W., Revelo, M.P., Shappell, S., Chen, Y.H. Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum Pathol. 36(10):1037-1048, 2005.
  68. Girasole, C.R., Cookson, M.S., Putzi, M.J., Chang, S.S., Smith, J.A., Jr., Wells, N., Oppenheimer, J.R., Shappell, S.B. Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy: Implications for cancer detection and biopsy strategy. J. Urol., 175:929-933; discussion 933, 2006.
  69. Nelson, B.A., Shappell, S.B., Chang, S.S., Wells, N., Fanham, S.B., Smith, J.A., Jr., Cookson, M.S., Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int., 97(6):1169-1172, 2006.
  70. Kelavkar, U.P., Parwani, A.V., Shappell, S.B., Martin, W.D. Conditional expression of human 15-Lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: The FLiMP mouse model. Neoplasia, 8(6):510-522, 2006.
  71. Faley, S.L., Takahashi, K., Crooke, C.E., Beckham, J.T., Tomemori, T., Shappell, S.B., Jansen, E.D., Takahashi, T. Bioluminescence imaging of vascular endothelial growth factor promoter activity in murine mammary tumorigenesis. Mol Imaging. Sep-Oct;6(5):331-339, 2007.
  72. Shappell, S.B. Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol. 10(1):44-69, 2008.
  73. Revelo, M.P., Cookson, M.S., Chang, S.S., Shook, M.F., Smith, J.A. Jr, Shappell, S.B. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol., 179(5 Suppl):S27-32, 2008.